SEC Form 4 · accession 0000899243-16-016919
Coherus Oncology, Inc. · CHRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean-Frederic Viret
Officer — Chief Financial Officer
Period of report
Mar 28, 2016
Accepted (ET)
Mar 30, 2016 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001512762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value | Mar 28, 2016 | M | 400 | $13.50 | A | 400 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $13.50 | Mar 28, 2016 | M | 400 | D | — | Nov 5, 2024 | Common Stock | 400 | 134,573 | D |
Explanation of responses
- F1The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest one year measured from September 22, 2014 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.